LifeStance Health Group, Inc. (NASDAQ:LFST) Short Interest Update

LifeStance Health Group, Inc. (NASDAQ:LFST) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 9,860,000 shares, a decline of 10.1% from the December 15th total of 10,970,000 shares. Based on an average daily volume of 1,460,000 shares, the days-to-cover ratio is currently 6.8 days. Currently, 8.9% of the company’s shares are short sold.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group upgraded shares of LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a report on Monday, December 16th. Barclays increased their price objective on LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.70.

LifeStance Health Group Stock Performance

Shares of LFST opened at $7.99 on Friday. LifeStance Health Group has a 1-year low of $4.64 and a 1-year high of $9.20. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. The firm’s 50-day moving average price is $7.44 and its 200-day moving average price is $6.72.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.66%. The business had revenue of $312.70 million during the quarter, compared to analyst estimates of $302.25 million. During the same period last year, the business posted ($0.17) earnings per share. LifeStance Health Group’s quarterly revenue was up 18.9% compared to the same quarter last year. As a group, equities analysts expect that LifeStance Health Group will post -0.2 earnings per share for the current year.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, Director Robert Bessler sold 75,000 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total value of $565,500.00. Following the sale, the director now owns 1,424,447 shares of the company’s stock, valued at $10,740,330.38. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Hedge funds have recently made changes to their positions in the company. Algert Global LLC purchased a new position in LifeStance Health Group during the 2nd quarter valued at about $57,000. Victory Capital Management Inc. increased its stake in shares of LifeStance Health Group by 27.0% during the second quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock valued at $71,000 after purchasing an additional 3,063 shares in the last quarter. Park Edge Advisors LLC purchased a new position in shares of LifeStance Health Group during the third quarter valued at approximately $73,000. Townsquare Capital LLC bought a new stake in shares of LifeStance Health Group in the 3rd quarter worth approximately $73,000. Finally, Dark Forest Capital Management LP purchased a new stake in shares of LifeStance Health Group in the 2nd quarter worth approximately $81,000. 85.50% of the stock is currently owned by institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.